Literature DB >> 17551966

Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis.

Charalambos Antoniades1, Dimitris Tousoulis, Kyriakoula Marinou, Nikos Papageorgiou, Erini Bosinakou, Costas Tsioufis, Elli Stefanadi, George Latsios, Costas Tentolouris, Gerasimos Siasos, Christodoulos Stefanadis.   

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is characterized by endothelial dysfunction, increased thrombogenicity and abnormal inflammatory response. HYPOTHESIS: We hypothesizsed that insulin dependence/exogenous insulin administration may affect thrombotic/inflammatory status and endothelial function in patients with T2DM and coronary artery disease (CAD).
METHODS: Fifty-five patients with T2DM + CAD (26 insulin-treated (INS) and 29 under oral biguanide + sulphonylurea (TABL)) were recruited. Endothelial function was assessed by gauge-strain plethysmography, and serum levels of inflammatory and thrombotic markers were determined by enzyme linked immunosorbent assay.
RESULTS: There was no significant difference in endothelium-dependent dilation (EDD) between the study groups, while EDD was correlated with fasting glucose levels in both INS (r = - 0.776, p = 0.0001) and TABL (r = - 0.702, p = 0.0001). Patients in INS group had higher levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), monocyte chemoattractant protein (MCP-1) and vascular cell adhesion molecule (sVCAM-1), compared to TABL. However, TNF-alpha was negatively correlated with protein C (PrtC) only in INS (r = - 0.726, p = 0.01) but not in TABL group (r = - 0.066, p = 0.738). Similarly, sVCAM-1 was correlated with PrtC only among INS patients (r = - 0.451, p = 0.046) but not in TABL (r = 0.069, p = 0.727). In multivariate analysis, insulin dependence was a predictor of IL-6, TNF-alpha, MCP-1 and sVCAM-1 levels independently from the patients' demographic characteristics, the angiographic extend of CAD or the duration of diabetes.
CONCLUSIONS: Insulin treatment in patients with type 2 diabetes mellitus affects the expression of inflammatory cytokines and subsequently modifies the thrombotic mechanisms in patients with coronary atherosclerosis, independently from the duration of diabetes and the extend of coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551966      PMCID: PMC6653670          DOI: 10.1002/clc.20101

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  27 in total

1.  Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study.

Authors:  M Pyörälä; H Miettinen; M Laakso; K Pyörälä
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

Review 2.  The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm.

Authors:  P Dandona; A Aljada; P Mohanty
Journal:  Diabetologia       Date:  2002-06       Impact factor: 10.122

Review 3.  Diabetes and endothelial dysfunction: a clinical perspective.

Authors:  J Calles-Escandon; M Cipolla
Journal:  Endocr Rev       Date:  2001-02       Impact factor: 19.871

4.  Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells.

Authors:  A Aljada; H Ghanim; R Saadeh; P Dandona
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

5.  Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor-alpha, interleukin-1, and transforming growth factor-beta.

Authors:  K Yamamoto; T Shimokawa; T Kojima; D J Loskutoff; H Saito
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

6.  Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide.

Authors:  A Aljada; R Saadeh; E Assian; H Ghanim; P Dandona
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

7.  Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells.

Authors:  I Golovchenko; M L Goalstone; P Watson; M Brownlee; B Draznin
Journal:  Circ Res       Date:  2000-10-27       Impact factor: 17.367

Review 8.  Diabetes mellitus: a hypercoagulable state.

Authors:  M E Carr
Journal:  J Diabetes Complications       Date:  2001 Jan-Feb       Impact factor: 2.852

9.  Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?

Authors:  P Dandona; A Aljada; P Mohanty; H Ghanim; W Hamouda; E Assian; S Ahmad
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

Review 10.  Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.

Authors:  N Unwin; J Shaw; P Zimmet; K G M M Alberti
Journal:  Diabet Med       Date:  2002-09       Impact factor: 4.359

View more
  14 in total

Review 1.  Targeting inflammation in diabetes: Newer therapeutic options.

Authors:  Neeraj Kumar Agrawal; Saket Kant
Journal:  World J Diabetes       Date:  2014-10-15

Review 2.  Mitochondria and cardiovascular diseases-from pathophysiology to treatment.

Authors:  Gerasimos Siasos; Vasiliki Tsigkou; Marinos Kosmopoulos; Dimosthenis Theodosiadis; Spyridon Simantiris; Nikoletta Maria Tagkou; Athina Tsimpiktsioglou; Panagiota K Stampouloglou; Evangelos Oikonomou; Konstantinos Mourouzis; Anastasios Philippou; Manolis Vavuranakis; Christodoulos Stefanadis; Dimitris Tousoulis; Athanasios G Papavassiliou
Journal:  Ann Transl Med       Date:  2018-06

3.  Effects of insulin on the proliferation and global gene expression profile of A7r5 cells.

Authors:  Huiming Duan; Xiaotao Feng; Xiaoqi Huang
Journal:  Mol Biol Rep       Date:  2021-02-08       Impact factor: 2.316

4.  Insulin therapy does not interfere with venous endothelial function evaluation in patients with type 2 diabetes mellitus.

Authors:  Antônio Marcos Vargas da Silva; Luciana de Moraes Penno; Marcello Casaccia Bertoluci; Maria Cláudia Irigoyen; Beatriz D'Agord Schaan
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

5.  Plasma levels of copeptin in patients with coronary heart disease.

Authors:  San Bao Chai; Yong Ming Hui; Xue Min Li; Yang Xiao; Chao Shu Tang
Journal:  Heart Vessels       Date:  2009-04-01       Impact factor: 2.037

6.  Is chronic inflammation a possible cause of obesity-related depression?

Authors:  Magdalena Olszanecka-Glinianowicz; Barbara Zahorska-Markiewicz; Piotr Kocełak; Joanna Janowska; Elzbieta Semik-Grabarczyk; Tomasz Wikarek; Wojciech Gruszka; Piotr Dabrowski
Journal:  Mediators Inflamm       Date:  2009-06-29       Impact factor: 4.711

7.  Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.

Authors:  Craig J Currie; Chris D Poole; Marc Evans; John R Peters; Christopher Ll Morgan
Journal:  J Clin Endocrinol Metab       Date:  2013-01-31       Impact factor: 5.958

Review 8.  Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets.

Authors:  Akira Mima
Journal:  J Diabetes Res       Date:  2013-06-03       Impact factor: 4.011

9.  Inflammation Modulates RLIP76/RALBP1 Electrophile-Glutathione Conjugate Transporter and Housekeeping Genes in Human Blood-Brain Barrier Endothelial Cells.

Authors:  Barbara Bennani-Baiti; Stefan Toegel; Helmut Viernstein; Ernst Urban; Christian R Noe; Idriss M Bennani-Baiti
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

10.  Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines.

Authors:  Jong-Youn Kim; Eui-Young Choi; Hee-Sun Mun; Pil-Ki Min; Young-Won Yoon; Byoung Kwon Lee; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon
Journal:  Cardiovasc Diabetol       Date:  2013-10-02       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.